Corticosteroids in the treatment of severe community-acquired pneumonia.

Abstract

Controversy surrounds the use of adjunctive corticosteroids in severe community acquired pneumonia (CAP) as current guidelines either do not address or discourage their use. Double-blind, placebo-controlled, randomized controlled trials examining systemic corticosteroids in the treatment of severe CAP were summarized and their impacts on patient-important outcomes assessed. Four trials describing systemic corticosteroid use in adults with severe CAP were identified. One trial had a significant mortality difference favoring corticosteroids. However, this may be the result of a CAP severity imbalance within the trial and the mortality benefit was not confirmed in a larger trial conducted in a similar critical care setting. Pneumonia severity, mortality assessment timing, comorbidities, corticosteroid and antibiotic choice and timing in the CAP disease course, and bias risks varied across the four trials. Because of the clinical heterogeneity of available studies and the unknowns pertaining to clinical efficacy and safety, we do not recommend the use of adjunctive corticosteroids in severe CAP.

• Authors: Tasha D Ramsey, Sean K Gorman
• Journal: Current infectious disease reports (Curr Infect Dis Rep) Vol. 16 Issue 5 Pg. 405 (May 2014) ISSN: 1523-3847 [Print] United States
• PMID: 24817026 (Publication Type: Journal Article)